doi: 10.3389/fneur.2025.1627172 Received 12 May 2025 Accepted 12 September 2025 Published 26 September 2025 Volume 16 - 2025 Edited by Jean-Claude Baron, University of Cambridge, United Kingdom Reviewed by Richard Leigh, Johns Hopkins University, United States Ozge Altintas Kadirhan, Kirklareli University, Trkiye Updates Copyright 2025 Liao, Luo, Ma, Gao, Chen, Yan, He, Liu and Zhou
If you take insulin or a sulfonylurea, get individual advice before fasting
The expected outcomes of Semaglutide treatment will vary depending on the individuals starting weight
The introduction of GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) has fundamentally changed what is clinically achievable, with patients routinely losing 15-22% of their body weight under proper medical supervision